Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis

Mutations in the core RNA splicing factor SF3B1 are prevalent in leukemias and uveal melanoma, but hotspot SF3B1 mutations are also seen in epithelial malignancies such as breast cancer. Although hotspot mutations in SF3B1 alter hematopoietic differentiation, whether SF3B1 mutations contribute to ep...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of clinical investigation Ročník 131; číslo 1
Hlavní autoři:	Liu, Bo, Liu, Zhaoqi, Chen, Sisi, Ki, Michelle, Erickson, Caroline, Reis-Filho, Jorge S., Durham, Benjamin H., Chang, Qing, de Stanchina, Elisa, Sun, Yiwei, Rabadan, Raul, Abdel-Wahab, Omar, Chandarlapaty, Sarat
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States American Society for Clinical Investigation 04.01.2021
Témata:	Animals Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Carcinogenesis - genetics Carcinogenesis - metabolism Carcinogenesis - pathology Female Humans Mammary Neoplasms, Animal - genetics Mammary Neoplasms, Animal - metabolism Mammary Neoplasms, Animal - pathology Mice Mice, Transgenic Mutation NF-kappa B - genetics NF-kappa B - metabolism Phosphoproteins - genetics Phosphoproteins - metabolism Proto-Oncogene Proteins c-akt - genetics Proto-Oncogene Proteins c-akt - metabolism RNA Splicing Factors - genetics RNA Splicing Factors - metabolism RNA processing Oncology Breast cancer
ISSN:	0021-9738, 1558-8238, 1558-8238
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Mutations in the core RNA splicing factor SF3B1 are prevalent in leukemias and uveal melanoma, but hotspot SF3B1 mutations are also seen in epithelial malignancies such as breast cancer. Although hotspot mutations in SF3B1 alter hematopoietic differentiation, whether SF3B1 mutations contribute to epithelial cancer development and progression is unknown. Here, we identify that SF3B1 mutations in mammary epithelial and breast cancer cells induce a recurrent pattern of aberrant splicing leading to activation of AKT and NF-κB, enhanced cell migration, and accelerated tumorigenesis. Transcriptomic analysis of human cancer specimens, MMTV-cre Sf3b1K700E/WT mice, and isogenic mutant cell lines identified hundreds of aberrant 3' splice sites (3'ss) induced by mutant SF3B1. Consistently between mouse and human tumors, mutant SF3B1 promoted aberrant splicing (dependent on aberrant branchpoints as well as pyrimidines downstream of the cryptic 3'ss) and consequent suppression of PPP2R5A and MAP3K7, critical negative regulators of AKT and NF-κB. Coordinate activation of NF-κB and AKT signaling was observed in the knockin models, leading to accelerated cell migration and tumor development in combination with mutant PIK3CA but also hypersensitizing cells to AKT kinase inhibitors. These data identify hotspot mutations in SF3B1 as an important contributor to breast tumorigenesis and reveal unique vulnerabilities in cancers harboring them.
AbstractList	Mutations in the core RNA splicing factor SF3B1 are prevalent in leukemias and uveal melanoma, but hotspot SF3B1 mutations are also seen in epithelial malignancies such as breast cancer. Although hotspot mutations in SF3B1 alter hematopoietic differentiation, whether SF3B1 mutations contribute to epithelial cancer development and progression is unknown. Here, we identify that SF3B1 mutations in mammary epithelial and breast cancer cells induce a recurrent pattern of aberrant splicing leading to activation of AKT and NF-κB, enhanced cell migration, and accelerated tumorigenesis. Transcriptomic analysis of human cancer specimens, MMTV-cre Sf3b1K700E/WT mice, and isogenic mutant cell lines identified hundreds of aberrant 3' splice sites (3'ss) induced by mutant SF3B1. Consistently between mouse and human tumors, mutant SF3B1 promoted aberrant splicing (dependent on aberrant branchpoints as well as pyrimidines downstream of the cryptic 3'ss) and consequent suppression of PPP2R5A and MAP3K7, critical negative regulators of AKT and NF-κB. Coordinate activation of NF-κB and AKT signaling was observed in the knockin models, leading to accelerated cell migration and tumor development in combination with mutant PIK3CA but also hypersensitizing cells to AKT kinase inhibitors. These data identify hotspot mutations in SF3B1 as an important contributor to breast tumorigenesis and reveal unique vulnerabilities in cancers harboring them.Mutations in the core RNA splicing factor SF3B1 are prevalent in leukemias and uveal melanoma, but hotspot SF3B1 mutations are also seen in epithelial malignancies such as breast cancer. Although hotspot mutations in SF3B1 alter hematopoietic differentiation, whether SF3B1 mutations contribute to epithelial cancer development and progression is unknown. Here, we identify that SF3B1 mutations in mammary epithelial and breast cancer cells induce a recurrent pattern of aberrant splicing leading to activation of AKT and NF-κB, enhanced cell migration, and accelerated tumorigenesis. Transcriptomic analysis of human cancer specimens, MMTV-cre Sf3b1K700E/WT mice, and isogenic mutant cell lines identified hundreds of aberrant 3' splice sites (3'ss) induced by mutant SF3B1. Consistently between mouse and human tumors, mutant SF3B1 promoted aberrant splicing (dependent on aberrant branchpoints as well as pyrimidines downstream of the cryptic 3'ss) and consequent suppression of PPP2R5A and MAP3K7, critical negative regulators of AKT and NF-κB. Coordinate activation of NF-κB and AKT signaling was observed in the knockin models, leading to accelerated cell migration and tumor development in combination with mutant PIK3CA but also hypersensitizing cells to AKT kinase inhibitors. These data identify hotspot mutations in SF3B1 as an important contributor to breast tumorigenesis and reveal unique vulnerabilities in cancers harboring them. Mutations in the core RNA splicing factor SF3B1 are prevalent in leukemias and uveal melanoma, but hotspot SF3B1 mutations are also seen in epithelial malignancies such as breast cancer. Although hotspot mutations in SF3B1 alter hematopoietic differentiation, whether SF3B1 mutations contribute to epithelial cancer development and progression is unknown. Here, we identify that SF3B1 mutations in mammary epithelial and breast cancer cells induce a recurrent pattern of aberrant splicing leading to activation of AKT and NF-κB, enhanced cell migration, and accelerated tumorigenesis. Transcriptomic analysis of human cancer specimens, MMTV-cre Sf3b1K700E/WT mice, and isogenic mutant cell lines identified hundreds of aberrant 3' splice sites (3'ss) induced by mutant SF3B1. Consistently between mouse and human tumors, mutant SF3B1 promoted aberrant splicing (dependent on aberrant branchpoints as well as pyrimidines downstream of the cryptic 3'ss) and consequent suppression of PPP2R5A and MAP3K7, critical negative regulators of AKT and NF-κB. Coordinate activation of NF-κB and AKT signaling was observed in the knockin models, leading to accelerated cell migration and tumor development in combination with mutant PIK3CA but also hypersensitizing cells to AKT kinase inhibitors. These data identify hotspot mutations in SF3B1 as an important contributor to breast tumorigenesis and reveal unique vulnerabilities in cancers harboring them.
Author	Reis-Filho, Jorge S. Liu, Zhaoqi Durham, Benjamin H. Abdel-Wahab, Omar Chen, Sisi Liu, Bo Ki, Michelle de Stanchina, Elisa Sun, Yiwei Chang, Qing Chandarlapaty, Sarat Rabadan, Raul Erickson, Caroline
AuthorAffiliation	5 Department of Systems Biology and Department of Biomedical Informatics, Columbia University, New York, New York, USA 8 Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA 2 Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China 3 China National Center for Bioinformation, Beijing, China 6 Department of Pathology 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA 9 Weill-Cornell Medicine, New York, New York, USA 7 Antitumor Assessment Core and Molecular Pharmacology Department, and 10 Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA 4 Program for Mathematical Genomics
AuthorAffiliation_xml	– name: 1 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA – name: 2 Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China – name: 8 Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA – name: 9 Weill-Cornell Medicine, New York, New York, USA – name: 7 Antitumor Assessment Core and Molecular Pharmacology Department, and – name: 6 Department of Pathology – name: 3 China National Center for Bioinformation, Beijing, China – name: 5 Department of Systems Biology and Department of Biomedical Informatics, Columbia University, New York, New York, USA – name: 10 Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA – name: 4 Program for Mathematical Genomics
Author_xml	– sequence: 1 givenname: Bo surname: Liu fullname: Liu, Bo – sequence: 2 givenname: Zhaoqi surname: Liu fullname: Liu, Zhaoqi – sequence: 3 givenname: Sisi surname: Chen fullname: Chen, Sisi – sequence: 4 givenname: Michelle surname: Ki fullname: Ki, Michelle – sequence: 5 givenname: Caroline surname: Erickson fullname: Erickson, Caroline – sequence: 6 givenname: Jorge S. surname: Reis-Filho fullname: Reis-Filho, Jorge S. – sequence: 7 givenname: Benjamin H. orcidid: 0000-0001-8090-5448 surname: Durham fullname: Durham, Benjamin H. – sequence: 8 givenname: Qing surname: Chang fullname: Chang, Qing – sequence: 9 givenname: Elisa orcidid: 0000-0002-3873-315X surname: de Stanchina fullname: de Stanchina, Elisa – sequence: 10 givenname: Yiwei orcidid: 0000-0002-5974-6232 surname: Sun fullname: Sun, Yiwei – sequence: 11 givenname: Raul orcidid: 0000-0001-7946-9255 surname: Rabadan fullname: Rabadan, Raul – sequence: 12 givenname: Omar orcidid: 0000-0002-3907-6171 surname: Abdel-Wahab fullname: Abdel-Wahab, Omar – sequence: 13 givenname: Sarat orcidid: 0000-0003-4532-8053 surname: Chandarlapaty fullname: Chandarlapaty, Sarat
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33031100$$D View this record in MEDLINE/PubMed
BookMark	eNptkc1O3DAUha2KqjPQLngBlCVdhPFPEtsbJJh26NChLJiuLSe5AaPEHmwHqTvegbfhIXiIPkknAkYUsbqL-91zju7ZRlvWWUBol-ADQjidnE7nhAlG8g9oTPJcpIIysYXGGFOSSs7ECG2HcI0xybI8-4RGjGFGCMZj9O2sj9rG5GLGjkmy8q5zEUJy9HOZJtrWya9Z-vhw_PfuvvbmFmzS6a7T_k8S-855cwkWggmf0cdGtwG-PM8d9Hv2fTn9kS7OT-bTo0VaMZ7HVDSlwCXLhcSSS9A1bQBkowtOBTBZct40ZcYbSguNgRV1QSGTMme4zHVRYraDDp90V33ZQV2BjV63auXNkEk5bdT_G2uu1KW7VZxzxvggsP8s4N1NDyGqzoQK2lZbcH1QNBv8qJQDuvfaa2Py8ro18PUJqLwLwUOzQQhWQy1qU8uanbxhKxN1NG6Iadp3Lv4B7A6O_w
CitedBy_id	crossref_primary_10_1007_s00018_024_05515_6 crossref_primary_10_1093_ejendo_lvad114 crossref_primary_10_1111_iju_14830 crossref_primary_10_3389_fcell_2023_1232146 crossref_primary_10_1093_jb_mvae061 crossref_primary_10_1016_j_jbior_2024_101055 crossref_primary_10_1186_s13046_024_03030_x crossref_primary_10_1016_j_molcel_2024_07_019 crossref_primary_10_1186_s13045_021_01137_8 crossref_primary_10_1172_jci_insight_184280 crossref_primary_10_1093_jb_mvac049 crossref_primary_10_26508_lsa_202301955 crossref_primary_10_3389_fonc_2020_609409 crossref_primary_10_1016_j_molcel_2024_04_006 crossref_primary_10_1038_s41588_023_01460_5 crossref_primary_10_1186_s40164_022_00319_5 crossref_primary_10_1155_2022_1217918 crossref_primary_10_7554_eLife_80683 crossref_primary_10_3389_fphar_2024_1435545 crossref_primary_10_1158_2767_9764_CRC_24_0145 crossref_primary_10_1186_s13046_022_02241_4 crossref_primary_10_1186_s13046_022_02245_0 crossref_primary_10_1084_jem_20230891 crossref_primary_10_1016_j_celrep_2025_116075 crossref_primary_10_1186_s12935_024_03280_x
Cites_doi	10.1093/nar/25.21.4323 10.1038/s41586-019-1012-y 10.1038/nature11412 10.1038/s41586-019-1650-0 10.1016/j.ccell.2015.04.006 10.1074/jbc.M300609200 10.1016/j.ccell.2016.10.005 10.1038/sj.onc.1203412 10.1056/NEJMoa1607303 10.1056/NEJMoa1502309 10.1038/ni1255 10.1056/NEJMoa1706450 10.1016/j.immuni.2011.12.010 10.1056/NEJMoa1109016 10.1038/nature10496 10.1073/pnas.0900780106 10.1038/s41586-019-1618-0 10.1056/NEJM200103153441101 10.3791/55789 10.1182/blood.V124.21.828.828 10.1056/NEJMoa1113216 10.1038/nm.4493 10.1038/s41586-019-1651-z 10.1038/ng.2822 10.1056/NEJMoa1109653 10.1038/ng.1031 10.1172/JCI125022 10.1038/s41586-019-1056-z 10.1038/s41586-019-1646-9 10.1186/s13059-014-0550-8 10.1056/NEJMoa1103283 10.1038/s41598-017-17204-5 10.1158/1078-0432.CCR-12-3327 10.1172/JCI119848 10.1016/j.celrep.2018.01.088 10.1126/science.aaw9032 10.1371/journal.pcbi.1004105 10.1073/pnas.0506580102 10.1038/nature10983 10.1038/nbt.3391 10.1016/j.ccell.2016.08.006 10.3791/2828 10.1158/2159-8290.CD-19-1330 10.1158/0008-5472.CAN-14-2930 10.1016/j.ccell.2018.07.003 10.1172/JCI45014 10.1158/2159-8290.CD-12-0018 10.1158/0008-5472.CAN-10-0738 10.1016/j.cell.2015.09.033 10.1021/cb3005897 10.1056/NEJMoa1813904 10.1093/bioinformatics/btt656 10.1101/gr.181016.114 10.1158/2159-8290.CD-17-0321 10.1016/j.ccell.2018.11.006 10.1016/j.celrep.2015.09.053 10.1016/j.ccell.2018.08.008 10.1016/j.ccell.2018.10.003 10.1038/nature14669 10.1016/j.cell.2011.12.033 10.1016/j.ccell.2018.12.013 10.1056/NEJMoa1714448 10.1056/NEJMoa1500596
ContentType	Journal Article
Copyright	2021 American Society for Clinical Investigation 2021 American Society for Clinical Investigation
Copyright_xml	– notice: 2021 American Society for Clinical Investigation 2021 American Society for Clinical Investigation
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM
DOI	10.1172/JCI138315
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1558-8238
ExternalDocumentID	PMC7773370 33031100 10_1172_JCI138315
Genre	Research Support, U.S. Gov't, Non-P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NCI NIH HHS grantid: R01 CA245069 – fundername: NCI NIH HHS grantid: P30 CA008748
GroupedDBID	--- -~X .55 .XZ 08G 08P 29K 354 36B 5GY 5RE 5RS 7RV 7X7 88E 8AO 8F7 8FE 8FH 8FI 8FJ 8R4 8R5 AAWTL AAYXX ABOCM ABPMR ABUWG ACGFO ACIHN ACNCT ACPRK ADBBV ADPDF AEAQA AENEX AFCHL AFFHD AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS ASPBG AVWKF AZFZN BAWUL BBNVY BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBS EJD EMB EMOBN EX3 F5P FRP FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR IHW INH IOF IOV IPO ISR ITC KQ8 L7B LK8 M1P M5~ M7P NAPCQ OBH OCB ODZKP OFXIZ OGEVE OHH OK1 OVD OVIDX OVT P2P P6G PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X RPM S0X SJFOW SV3 TEORI TR2 TVE UKHRP VVN W2D WH7 WOQ WOW X7M XSB YFH YHG YKV YOC ZY1 ~H1 3V. 88A ALIPV CGR CUY CVF ECM EIF INR M0L NPM 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c375t-8fb80b35890979ead2fee9fa6728e39b77ffb47f226a0e36d62e499530b5a6b03
ISICitedReferencesCount	23
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000607625100003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0021-9738 1558-8238
IngestDate	Tue Nov 04 01:53:04 EST 2025 Fri Sep 05 07:26:00 EDT 2025 Thu Jan 02 22:56:43 EST 2025 Sat Nov 29 01:34:35 EST 2025 Tue Nov 18 22:24:01 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	RNA processing Oncology Breast cancer
Language	English
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c375t-8fb80b35890979ead2fee9fa6728e39b77ffb47f226a0e36d62e499530b5a6b03
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Authorship note: BL and ZL contributed equally to this work.
ORCID	0000-0001-7946-9255 0000-0003-4532-8053 0000-0002-5974-6232 0000-0002-3907-6171 0000-0002-3873-315X 0000-0001-8090-5448
OpenAccessLink	http://www.jci.org/articles/view/138315/files/pdf
PMID	33031100
PQID	2449952990
PQPubID	23479
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7773370 proquest_miscellaneous_2449952990 pubmed_primary_33031100 crossref_primary_10_1172_JCI138315 crossref_citationtrail_10_1172_JCI138315
PublicationCentury	2000
PublicationDate	2021-1-4 2021-01-04 20210104
PublicationDateYYYYMMDD	2021-01-04
PublicationDate_xml	– month: 01 year: 2021 text: 2021-1-4 day: 04
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	The Journal of clinical investigation
PublicationTitleAlternate	J Clin Invest
PublicationYear	2021
Publisher	American Society for Clinical Investigation
Publisher_xml	– name: American Society for Clinical Investigation
References	Ajibade (B40) 2012; 36 Hyman (B20) 2015; 373 Singh (B39) 2012; 148 Stanko (B59) 2017 Subramanian (B62) 2005; 102 Gucalp (B55) 2013; 19 Wagner (B36) 1997; 25 Cogswell (B44) 2000; 19 Adams (B32) 2011; 71 Darman (B37) 2015; 13 Sovak (B43) 1997; 100 Lee (B29) 2018; 34 Curtis (B23) 2012; 486 Diamond (B21) 2019; 567 B1 B2 B3 B4 Bertucci (B27) 2019; 569 Yin (B33) 2019; 35 B6 B7 B9 Chandarlapaty (B56) 2012; 2 Toy (B26) 2013; 45 Wu (B41) 2013; 8 Love (B64) 2014; 15 Vasan (B57) 2019; 366 Bankhead (B60) 2017; 7 Helbig (B42) 2003; 278 Baselga (B46) 2012; 366 Koren (B35) 2015; 525 Zhou (B30) 2015; 75 Bielski (B28) 2018; 34 Sato (B38) 2005; 6 Plante (B58) 2011 Cancer Genome Atlas (B22) 2012; 490 Liao (B63) 2014; 30 Pereira (B65) 2016; 7 Darman (B8) 2015; 13 Pratilas (B19) 2009; 106 B10 Finn (B49) 2016; 375 B54 B11 B12 Graubert (B5) 2011; 44 B13 B14 B15 B16 Razavi (B24) 2018; 34 B17 Ciriello (B50) 2015; 163 Robson (B53) 2017; 377 Slamon (B45) 2001; 344 Baselga (B48) 2012; 366 Drilon (B18) 2018; 378 Chang (B51) 2016; 34 Li (B61) 2018; 34 Liu (B34) 2020; 10 André (B47) 2019; 380 Chang (B25) 2018; 8 Le (B52) 2015; 372 Obeng (B31) 2014; 124
References_xml	– volume: 25 start-page: 4323 issue: 21 year: 1997 ident: B36 article-title: Cre-mediated gene deletion in the mammary gland publication-title: Nucleic Acids Res doi: 10.1093/nar/25.21.4323 – volume: 567 start-page: 521 issue: 7749 year: 2019 ident: B21 article-title: Efficacy of MEK inhibition in patients with histiocytic neoplasms publication-title: Nature doi: 10.1038/s41586-019-1012-y – volume: 490 start-page: 61 issue: 7418 year: 2012 ident: B22 article-title: Comprehensive molecular portraits of human breast tumours publication-title: Nature doi: 10.1038/nature11412 – ident: B6 doi: 10.1038/s41586-019-1650-0 – ident: B9 doi: 10.1016/j.ccell.2015.04.006 – volume: 278 start-page: 21631 issue: 24 year: 2003 ident: B42 article-title: NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4 publication-title: J Biol Chem doi: 10.1074/jbc.M300609200 – ident: B14 doi: 10.1016/j.ccell.2016.10.005 – volume: 19 start-page: 1123 issue: 9 year: 2000 ident: B44 article-title: Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3 publication-title: Oncogene doi: 10.1038/sj.onc.1203412 – volume: 375 start-page: 1925 issue: 20 year: 2016 ident: B49 article-title: Palbociclib and letrozole in advanced breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1607303 – volume: 373 start-page: 726 issue: 8 year: 2015 ident: B20 article-title: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations publication-title: N Engl J Med doi: 10.1056/NEJMoa1502309 – volume: 6 start-page: 1087 issue: 11 year: 2005 ident: B38 article-title: Essential function for the kinase TAK1 in innate and adaptive immune responses publication-title: Nat Immunol doi: 10.1038/ni1255 – volume: 377 start-page: 523 issue: 6 year: 2017 ident: B53 article-title: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa1706450 – volume: 36 start-page: 43 issue: 1 year: 2012 ident: B40 article-title: TAK1 negatively regulates NF-κB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils publication-title: Immunity doi: 10.1016/j.immuni.2011.12.010 – ident: B3 doi: 10.1056/NEJMoa1109016 – ident: B2 doi: 10.1038/nature10496 – volume: 106 start-page: 4519 issue: 11 year: 2009 ident: B19 article-title: (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0900780106 – ident: B12 doi: 10.1038/s41586-019-1618-0 – volume: 344 start-page: 783 issue: 11 year: 2001 ident: B45 article-title: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 publication-title: N Engl J Med doi: 10.1056/NEJM200103153441101 – issue: 125 year: 2017 ident: B59 article-title: Quantifying branching density in rat mammary gland whole-mounts using the sholl analysis method publication-title: J Vis Exp doi: 10.3791/55789 – volume: 124 issue: 21 year: 2014 ident: B31 article-title: Mutant splicing factor 3b subunit 1 (SF3B1) causes dysregulated erythropoiesis and a stem cell disadvantage publication-title: Blood doi: 10.1182/blood.V124.21.828.828 – volume: 366 start-page: 109 issue: 2 year: 2012 ident: B46 article-title: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1113216 – ident: B16 doi: 10.1038/nm.4493 – ident: B7 doi: 10.1038/s41586-019-1651-z – volume: 7 year: 2016 ident: B65 article-title: The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes publication-title: Nat Commun – volume: 45 start-page: 1439 issue: 12 year: 2013 ident: B26 article-title: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer publication-title: Nat Genet doi: 10.1038/ng.2822 – volume: 366 start-page: 520 issue: 6 year: 2012 ident: B48 article-title: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1109653 – volume: 44 start-page: 53 issue: 1 year: 2011 ident: B5 article-title: Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes publication-title: Nat Genet doi: 10.1038/ng.1031 – ident: B17 doi: 10.1172/JCI125022 – volume: 569 start-page: 560 issue: 7757 year: 2019 ident: B27 article-title: Genomic characterization of metastatic breast cancers publication-title: Nature doi: 10.1038/s41586-019-1056-z – ident: B11 doi: 10.1038/s41586-019-1646-9 – volume: 15 issue: 12 year: 2014 ident: B64 article-title: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 publication-title: Genome Biol doi: 10.1186/s13059-014-0550-8 – ident: B4 doi: 10.1056/NEJMoa1103283 – volume: 7 issue: 1 year: 2017 ident: B60 article-title: QuPath: open source software for digital pathology image analysis publication-title: Sci Rep doi: 10.1038/s41598-017-17204-5 – volume: 19 start-page: 5505 issue: 19 year: 2013 ident: B55 article-title: Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3327 – volume: 100 start-page: 2952 issue: 12 year: 1997 ident: B43 article-title: Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer publication-title: J Clin Invest doi: 10.1172/JCI119848 – ident: B1 doi: 10.1016/j.celrep.2018.01.088 – volume: 366 start-page: 714 issue: 6466 year: 2019 ident: B57 article-title: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors publication-title: Science doi: 10.1126/science.aaw9032 – ident: B15 doi: 10.1371/journal.pcbi.1004105 – volume: 102 start-page: 15545 issue: 43 year: 2005 ident: B62 article-title: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0506580102 – volume: 486 start-page: 346 issue: 7403 year: 2012 ident: B23 article-title: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups publication-title: Nature doi: 10.1038/nature10983 – volume: 34 start-page: 155 issue: 2 year: 2016 ident: B51 article-title: Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity publication-title: Nat Biotechnol doi: 10.1038/nbt.3391 – ident: B13 doi: 10.1016/j.ccell.2016.08.006 – issue: 53 year: 2011 ident: B58 article-title: Evaluation of mammary gland development and function in mouse models publication-title: J Vis Exp doi: 10.3791/2828 – volume: 10 start-page: 806 issue: 6 year: 2020 ident: B34 article-title: Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-19-1330 – volume: 75 start-page: 1949 issue: 10 year: 2015 ident: B30 article-title: A chemical genetics approach for the functional assessment of novel cancer genes publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-2930 – volume: 34 start-page: 225 issue: 2 year: 2018 ident: B29 article-title: Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.07.003 – ident: B54 doi: 10.1172/JCI45014 – volume: 2 start-page: 311 issue: 4 year: 2012 ident: B56 article-title: Negative feedback and adaptive resistance to the targeted therapy of cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0018 – volume: 71 start-page: 2706 issue: 7 year: 2011 ident: B32 article-title: Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-0738 – volume: 163 start-page: 506 issue: 2 year: 2015 ident: B50 article-title: Comprehensive molecular portraits of invasive lobular breast cancer publication-title: Cell doi: 10.1016/j.cell.2015.09.033 – volume: 8 start-page: 643 issue: 3 year: 2013 ident: B41 article-title: Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-oxozeaenol publication-title: ACS Chem Biol doi: 10.1021/cb3005897 – volume: 380 start-page: 1929 issue: 20 year: 2019 ident: B47 article-title: Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1813904 – volume: 30 start-page: 923 issue: 7 year: 2014 ident: B63 article-title: featureCounts: an efficient general purpose program for assigning sequence reads to genomic features publication-title: Bioinformatics doi: 10.1093/bioinformatics/btt656 – ident: B10 doi: 10.1101/gr.181016.114 – volume: 8 start-page: 174 issue: 2 year: 2018 ident: B25 article-title: Accelerating discovery of functional mutant alleles in cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0321 – volume: 34 start-page: 893 issue: 6 year: 2018 ident: B61 article-title: Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.11.006 – volume: 13 start-page: 1033 issue: 5 year: 2015 ident: B37 article-title: Cancer-associated SF3B1 hotspot mutations induce cryptic 3’ splice site selection through use of a different branch point publication-title: Cell Rep doi: 10.1016/j.celrep.2015.09.053 – volume: 34 start-page: 427 issue: 3 year: 2018 ident: B24 article-title: The genomic landscape of endocrine-resistant advanced breast cancers publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.08.008 – volume: 34 start-page: 852 issue: 5 year: 2018 ident: B28 article-title: Widespread selection for oncogenic mutant allele imbalance in cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.10.003 – volume: 13 start-page: 1033 issue: 5 year: 2015 ident: B8 article-title: Cancer-associated SF3B1 hotspot mutations induce cryptic 3′ splice site selection through use of a different branch point publication-title: Cell Rep doi: 10.1016/j.celrep.2015.09.053 – volume: 525 start-page: 114 issue: 7567 year: 2015 ident: B35 article-title: PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours publication-title: Nature doi: 10.1038/nature14669 – volume: 148 start-page: 639 issue: 4 year: 2012 ident: B39 article-title: TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers publication-title: Cell doi: 10.1016/j.cell.2011.12.033 – volume: 35 start-page: 283 issue: 2 year: 2019 ident: B33 article-title: A murine model of chronic lymphocytic leukemia based on B cell-restricted expression of sf3b1 mutation and atm deletion publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.12.013 – volume: 378 start-page: 731 issue: 8 year: 2018 ident: B18 article-title: Efficacy of arotrectinib in TRK fusion-positive cancers in adults and children publication-title: N Engl J Med doi: 10.1056/NEJMoa1714448 – volume: 372 start-page: 2509 issue: 26 year: 2015 ident: B52 article-title: PD-1 Blockade in tumors with mismatch-repair deficiency publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596
SSID	ssj0014454
Score	2.4943492
Snippet	Mutations in the core RNA splicing factor SF3B1 are prevalent in leukemias and uveal melanoma, but hotspot SF3B1 mutations are also seen in epithelial...
SourceID	pubmedcentral proquest pubmed crossref
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source
SubjectTerms	Animals Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Carcinogenesis - genetics Carcinogenesis - metabolism Carcinogenesis - pathology Female Humans Mammary Neoplasms, Animal - genetics Mammary Neoplasms, Animal - metabolism Mammary Neoplasms, Animal - pathology Mice Mice, Transgenic Mutation NF-kappa B - genetics NF-kappa B - metabolism Phosphoproteins - genetics Phosphoproteins - metabolism Proto-Oncogene Proteins c-akt - genetics Proto-Oncogene Proteins c-akt - metabolism RNA Splicing Factors - genetics RNA Splicing Factors - metabolism
Title	Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis
URI	https://www.ncbi.nlm.nih.gov/pubmed/33031100 https://www.proquest.com/docview/2449952990 https://pubmed.ncbi.nlm.nih.gov/PMC7773370
Volume	131
WOSCitedRecordID	wos000607625100003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1558-8238 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014454 issn: 0021-9738 databaseCode: M7P dateStart: 20020701 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1558-8238 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014454 issn: 0021-9738 databaseCode: 7X7 dateStart: 20020701 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1558-8238 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014454 issn: 0021-9738 databaseCode: 7RV dateStart: 20020701 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1558-8238 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014454 issn: 0021-9738 databaseCode: BENPR dateStart: 20020701 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dbtMwFLbKhqbdIP4pP1VATEKqDImdxMnlWloxoFW1DVRxEyWprUVa09KfaZe8A7c8CQ_BQ_AkHDuxk65cABI3VuW4seXvy_E59jnHCD0XJOEBoyG2BXexS1MHJyQhOOUup2HMiXAm6rIJNhwG43E4ajS-6ViYi3OW58HlZTj_r1BDHYAtQ2f_Am7zUqiA3wA6lAA7lH8E_GAtLwZun_Rpx5HuV4AFX7ZBl8PqoGDYxwfd3kHnsKP9HOhkIUVeexqrOLb2aj2V12VJIZgt68prFUamFFgTVJlVuTqqQ_332VpxZ3al4tNZPPucVV4Fhdg7yZam7l2m_fnloUJ9W4I4alui2pY0501159OuHtfR1rh0aIGDQ1ake3nJS4nsBTggZZ0W2eXKUePm9lLAZGrZt90jB4zwImS0hv58quCnsILLpHnVamh8FEeDLmOMUmZfQ7uEeaGUmWxszHmwRL0yx3cx6DJvFfT7yvS6j_Z0F5uKz5Y1c9Upt6blnN5EN0p0rcOCVrdQg-e30d6gdMC4g14X7LIUuyzNLkuyywJ2WcCuH987P798LThllZyyNjh1F33o9067b3B5EQdOKfNWOBBJYCfUC0I7ZCHIHiI4D0XsMxLAF50wJkTiMgGqfGxz6k98wsGS9qideLGf2PQe2slnOX-ArAkYtO7E95zYhTU6luIgpqlgUnPlqfCb6IWepSgts9TLy1LOI2WtMhKZuW2iZ6bpvEjN8rtGT_VURyA45WlYnPPZehmBXgtDlNpYE90vpt68RmPWRGwDFNNAJmXffJJnZyo5e8mZh__8z0dov_qeHqOd1WLNn6Dr6cUqWy5aQMHjjy1FRFUGLbTb6Q1Hxy3ptTz6BcNJte8
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mutant+SF3B1+promotes+AKT-+and+NF-%CE%BAB%E2%80%93driven+mammary+tumorigenesis&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Liu%2C+Bo&rft.au=Liu%2C+Zhaoqi&rft.au=Chen%2C+Sisi&rft.au=Ki%2C+Michelle&rft.date=2021-01-04&rft.pub=American+Society+for+Clinical+Investigation&rft.issn=0021-9738&rft.eissn=1558-8238&rft.volume=131&rft.issue=1&rft_id=info:doi/10.1172%2FJCI138315&rft_id=info%3Apmid%2F33031100&rft.externalDocID=PMC7773370
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon